| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Nicole Boczek, Ph.D., and Sarah Barnett, M.S., CGC, explain how Mayo Clinic Laboratories' whole genome sequencing provides comprehensive information for rapid diagnosis of hereditary disorders.
Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories’ new marijuana monitoring evaluation, which identifies metabolites of both delta-9 tetrahydrocannabinol (THC) and delta-8 THC to accurately identify and characterize patients’ marijuana use.
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.
In January 2023, Mayo Clinic Laboratories announced fifty-nine new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
This page includes updates posted to the site during the month of January.
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of eosinophil-derived neurotoxins.
In December 2022, Mayo Clinic Laboratories announced seventy-eight new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
This page includes updates posted to the site during the month of December.
Offering increased sensitivity and improved accuracy, MayoComplete next-generation testing ensures health care providers understand the distinctive genetic features of their patients’ cancer to make informed decisions to guide their care.
This list includes updates posted to mayocliniclabs.com during the month of November.
In November 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.